| Biomarker ID | 1444 |
| PMID | 24961912 |
| Year | 2014 |
| Biomarker | Methylation status of genes (GSTM2; GSTP1; RARB; ALOX12; APC; PDGFRB; SCGB3A1; CFTR; MT1A; PENK; TERT; CCNA1; RARA; TAL1; ERG; MET; GFI1; MYCL2; SEPT9; COL18A1; KLK10; MFAP4; MMP14; TBX1; EYA4; NEU1; POMC; GADD45A; HTR1B; RASSF1; CDH13; PDGFRA; IRAK3; ASCL2; ESR1; HFE; IGFBP7; RARRES1; CAV1; THY1; BMP4;) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Pca |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 83 tumor and 10 normal prostate samples were selected for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | GoldenGate Methylation Cancer Panel I (Illumina, Inc.) |
| Clinical | No |
| Remarks | Significantly hypermethylated in more than 20% of the tumors analyzed |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | GSTM2, GSTP1, RARB, ALOX12, APC, PDGFRB, SCGB3A1, CFTR, MT1A, PENK, TERT, CCNA1, RARA, TAL1, ERG, MET, GFI1, MYCL2, SEPT9, COL18A1, KLK10, MFAP4, MMP14, TBX1, EYA4, NEU1, POMC, GADD45A, HTR1B, RASSF1, CDH13, PDGFRA, IRAK3, ASCL2, ESR1, HFE, IGFBP7, RARRES1, CAV1, THY1, BMP4 |